Rivanicline

Rivanicline
Systematic (IUPAC) name
(E)-N-Methyl-4-(3-pyridinyl)-3-butene-1-amine
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 538-79-4
ATC code None
PubChem CID 5310967
UNII 6H35LF645A Y
Chemical data
Formula C10H14N2 
Mol. mass 162.232
SMILES eMolecules & PubChem
 Y(what is this?)  (verify)

Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It has nootropic effects and was originally developed as a potential treatment for Alzheimer's disease,[1][2] but a second action that was subsequently found was that it inhibits the production of Interleukin-8 and thus produces an antiinflammatory effect, and so it has also been developed as a potential treatment for ulcerative colitis.[3] Rivanicline also has stimulant and analgesic actions which are thought to be mediated through stimulation of noradrenaline release,[4] and so it could potentially also have other applications.

References

  1. ^ Jang J, Sin KS, Park H. Synthesis of (+/-)-methyl-(1-aryl-4-pyridin-3-yl-but-3-enyl)-amines. Archives of Pharmacal Research. 2001 Dec;24(6):503-7. PMID 11794523
  2. ^ Sapronov NS, Fedotova YO, Kuznetsova NN. Antiamnestic effect of alpha7-nicotinic receptor agonist RJR-2403 in middle-aged ovariectomized rats with Alzheimer type dementia. Bulletin of Experimental Biology and Medicine. 2006 Dec;142(6):700-2. PMID 17603674
  3. ^ Spoettl T, Paetzel C, Herfarth H, Bencherif M, Schoelmerich J, Greinwald R, Gatto GJ, Rogler G. (E)-metanicotine hemigalactarate (TC-2403-12) inhibits IL-8 production in cells of the inflamed mucosa. International Journal of Colorectal Disease. 2007 Mar;22(3):303-12. PMID 16715250
  4. ^ Li X, Eisenach JC. Nicotinic acetylcholine receptor regulation of spinal norepinephrine release. Anesthesiology. 2002 Jun;96(6):1450-6. PMID 12170059